[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

NVO

Eli Lilly's new 'Triple G' drug Retatrutide shows significant weight loss, potentially redefining the medical weight loss ceiling and intensifying competition with Novo Nordisk.

About NVO

Novo Nordisk is a pharmaceutical company specializing in diabetes and obesity treatments.

Insights

nvo creators is up XXXXX% from the previous week.
nvo engagements is up XXXXX% from the previous week.
nvo posts created is up XXXXX% from the previous week.

Engagements: XXXXXXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXXXX
Daily Average: XXXXXXX
X Week: XXXXXXX +66%
X Month: XXXXXXX -XX%
X Months: XXXXXXXXXXX +38%
X Year: XXXXXXXXXXX +142%
1-Year High: XXXXXXXXX on 2025-06-23
1-Year Low: XX on 2025-12-04

Engagements by network (24h): News: XX Reddit: XXX TikTok: XXXXXX X: XXXXXXX YouTube: XXXXXX

Mentions: XXX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXXXX
X Week: XXXXX +7.70%
X Month: XXXXX -XXXX%
X Months: XXXXXX +57%
X Year: XXXXXX +96%
1-Year High: XXXXX on 2025-06-25
1-Year Low: X on 2025-12-04

Mentions by network (24h): News: X Reddit: XXX TikTok: XXX X: XXXXX YouTube: XXX

Creators: XXX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XXX unique social accounts have posts mentioning NVO in the last XX hours which is down XX% from XXX in the previous XX hours Daily Average: XXX
X Week: XXX +13%
X Month: XXXXX -XXXX%
X Months: XXXXXX +92%
X Year: XXXXXX +101%
1-Year High: XXXXX on 2025-06-25
1-Year Low: X on 2025-12-04

The most influential creators that mention NVO in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@Korkmazumut27	X	XX	X	XXX
@edgaralandough2	X	XXXXX	X	XX
@byul_finance	X	XXX	X	X
@AponiaAnalytics	X	XXXXX	X	X
@ElliotHenr81571	X	XX	X	X
@grok	X	XXXXXXXXX	X	X

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% +7%
X Month: XX% -X%
X Months: XX% +8%
X Year: XX% +11%
1-Year High: XXX% on 2025-10-31
1-Year Low: XX% on 2025-12-06

Most Supportive Themes:

Market Dominance in Diabetes and Obesity: (35%) Novo Nordisk's strong position in the diabetes and obesity market, with analysts predicting significant sales growth and a favorable valuation compared to competitors.
Analyst Upgrades and Doctor Recommendations: (25%) HSBC upgrades Novo Nordisk to Buy, citing an undervalued pipeline and a stronger focus on direct-to-consumer channels, while European doctors recommend Wegovy/Ozempic as first-line treatments for obesity.
Strategic Expansion and Partnerships: (15%) Novo Nordisk's strategic moves, such as partnerships with telehealth platforms and expansion into new markets like India, are seen as positive steps to maintain market share and drive future growth.

Most Critical Themes:

Restructuring and Job Cuts Concerns: (20%) The company's restructuring plan, including significant job cuts, raises concerns about morale, leadership, and the ability to maintain growth in a competitive market.
Increased Competition and Pricing Pressure: (5%) Increased competition from Eli Lilly (LLY) and generic copycats, along with supply chain issues and political pressure on drug pricing, pose challenges to Novo Nordisk's market share and profitability.

Top NVO News

Top news links shared on social in the last XX hours

Showing a maximum of X news posts for non-authenticated requests. Use your API key in requests for full results.

"Novo Nordisk A/S (NVO): A Bull Case Theory"
News Link @YahooFinance 2025-12-04T18:34Z 228.6M followers, 5279 engagements

NVO